{
  "url": "https://openlegislation.uk/eu-regulation-1995-1442/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-1995-1442/annex.json",
  "legislation": "eur/1995/1442",
  "legislation_title": "Commission Regulation (EC) No 1442/95 of 26 June 1995 amending Annexes I, II, III and IV of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-1995-1442",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Regulation (EEC) No 2377/90 is amended as follows:\nA.. Annex I is modified as follows:\n1.. Anti-infectious agents\n1.2. Antibiotics\n1.2.4. Macrolides\nPharmacologically active substance(s)\nMarker residue\nAnimal species\nMRLs\nTarget tissues\nOther provisions\n‘1.2.4.3.\nSpiramycin\nSum of spiramycin and neospiramycin\nBovine\n300 μg/kg\nLiver, kidney, fat\n200 μg/kg\nMuscle\n200 μg/kg\nMilk\nChicken\n400 μg/kg\nLiver\n300 μg/kg\nFat + skin\n200 μg/kg\nMuscle’\n2.. Antiparasitic agents\n2.2. Agents acting against ectoparasites\n2.2.3. Organophosphates\nPharmacologically active substance(s)\nMarker residue\nAnimal species\nMRLs\nTarget tissues\nOther provisions\n‘2.2.3.1.\nDiazinon\nDiazinon\nBovine, ovine, caprine,\n700 μg/kg\nporcine\nFat\n20 μg/kg\nKidney, liver, muscle\nBovine, ovine, caprine\n20 μg/kg\nMilk’\n3.. Agents acting on the nervous system\n3.2. Agents acting on the autonomic nervous system\n3.2.1. Anti-adrenergics\nPharmacologically active substance(s)\nMarker residue\nAnimal species\nMRLs\nTarget tissues\nOther provisions\n‘3.2.1.1.\nCarazolol\nCarazolol\nPorcine\n25 μg/kg\nLiver, kidney\n5 μg/kg\nMuscle, fat, + skin’\nB.. In Annex II the following headings are added:\n1.. Inorganic chemicals\nPharmacologically Active Substance(s)\nAnimal Species\nOther provisions\n‘1.6.\nHydrochloric acid\nAll food producing species\nFor use as excipient\n1.7.\nSodium dichloroisocyanurate\nBovine, ovine, caprine\nFor topical use only’\n2.. Organic chemicals\nPharmacologically Active Substance(s)\nAnimal Species\nOther provisions\n‘2.20.\nLecirelin\nBovine, equidae, rabbit\n2.21.\nDinoprost tromethamine\nAll mammalian species\n2.22.\nMalic acid\nAll food producing species\nFor use as excipient\n2.23.\nL-tartaric acid and its mono- and di-basic salt of sodium, potassium and calcium\nAl food producing species\nFor use as excipient\n2.24.\nBenzylalcohol\nAll food producing species\nFor use as excipient\n2.25.\nEthanol\nAll food producing species\nFor use as excipient\n2.26.\nN-butanol\nAll food producing species\nFor use as excipient’\nC.. Annex III is modified as follows:\n1.. Anti-infectious agents\n1.2. Antibiotics\n1.2.2. Macrolides\nPharmacologically Active substance(s)\nMarker Residue\nAnimal Species\nMRLs\nTarget Tissues\nOther provisions\n‘1.2.2.1.\nSpiramycin\nSpiramycin\nPorcine\n600 μg/kg\nLiver\nProvisional MRLs expire on 1 July 1997\nMRLs apply to all microbiological active residues expressed as Spiramycin-equivalent\n300 μg/kg\nKidney, muscle\n200 μg/kg\nFat\n1.2.2.2.\nTylosin\nTylosin\nBovine, Porcine, Poultry\n100 μg/kg\nMuscle, liver, kidney\nProvisional MRLs expire on 1 July 1997\nBovine\n50 μg/kg\nMilk\n1.2.2.3.\nErythromycin\nErythromycin\nBovine, ovine, porcine, poultry\n400 μg/kg\nLiver, kidney, muscle, fat\nProvisional MRLs expire on 1 June 2000\nMRLs apply to all microbiological active residues expressed as Erythromycin-equivalent’\nBovine, ovine\n40 μg/kg\nMilk\nPoultry\n200 μg/kg\nEggs\n1.2.4. Quinolones\nPharmacologically Active substance(s)\nMarker Residue\nAnimal Species\nMRLs\nTarget Tissues\nOther provisions\n‘1.2.4.1.\nDanofloxacin\nDanofloxacin\nBovine\n900 μg/kg\nLiver\nProvisional MRLs expire on 1 July 1997’\n500 μg/kg\nKidney\n300 μg/kg\nMuscle\n200 μg/kg\nFat\nChicken\n1 200 μg/kg\nLiver, kidney\n600 μg/kg\nFat + skin\n300 μg/kg\nMuscle\nD.. Annex IV is modified as follows:\nList of pharmacologically active substances for which no maximum residue limits can be fixed\n‘5.\nFurazolidon’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/1995/1442/annex",
    "retrieved_at": "2026-11-01T14:59:37.006547+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}